Adalimumab - MedImmune/AbbVie

Drug Profile

Adalimumab - MedImmune/AbbVie

Alternative Names: ABT-D2E7; D2E7; Humira; LU 200134; Raheara

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer AbbVie; Eisai Co Ltd; Interstitial Cystitis Study
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis; Hidradenitis suppurativa
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Behcet's syndrome; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis; Ulcerative colitis; Uveitis
  • Phase III Pustular psoriasis; Pyoderma
  • Discontinued Interstitial cystitis

Most Recent Events

  • 17 Oct 2017 Phase-III clinical trials in Pyoderma in Japan (SC) (NCT03311464)
  • 28 Sep 2017 Amgen enters into global settlement agreement with Abbvie related to patent litigation regarding adalimumab biosimilar
  • 21 Jul 2017 Committee for Medicinal Products for Human Use (CHMP) of the EMA recommends approval of adalimumab for Uveitis (In children, In adolescents) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top